Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment

Kazia Therapeutics ( (KZIA) ) has provided an announcement.

Kazia Therapeutics announced findings that highlight the potential of their lead product candidate, paxalisib, in treating difficult cases of breast cancer. At the San Antonio Breast Cancer Symposium, preclinical data demonstrated that paxalisib, when combined with pembrolizumab, showed promising results in models of immunotherapy-resistant triple negative breast cancer. Additionally, paxalisib combined with olaparib showed potential in HER2 positive metastatic breast cancer with active brain metastases, suggesting new avenues for treatment in patients who have exhausted standard therapies.

More about Kazia Therapeutics

Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. Their lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, primarily developed for brain cancer treatment. The company is involved in several clinical trials, including those for glioblastoma and other brain-related conditions, and has been granted multiple designations by the FDA for its innovative treatments.

YTD Price Performance: -18.41%

Average Trading Volume: 150,430

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $15.63M

Find detailed analytics on KZIA stock on TipRanks’ Stock Analysis page.